Comparison of the Accuracy of US, MRI and PET/CT in the Assessment of LNs in Cervical Cancer.

NCT ID: NCT05573451

Last Updated: 2024-09-25

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 91 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-01-20
• Study Completion Date: 2024-12-31

Brief Summary

Lymph node involvement is the most important negative prognostic factor in cervical cancer. Reliable preoperative lymph node assessment is of utmost importance to tailor the treatment. According to the current European guidelines local extent of the disease can be assessed by magnetic resonance imaging (MRI) or by ultrasound (US), if performed by properly trained sonographer. Positron emission tomography combined with computed tomography (PET/CT) is used as a reference standard for preoperative evaluation of lymph nodes. Another technique to assess nodes combining morphological and functional characteristics is diffusion-weighted MRI (DW/MRI). While US is considered the adequate alternative to MRI in local staging of cervical cancer, there is no relevant evidence of diagnostic performace of US in nodal assessment. However, retrospective analysis of diagnostic accuracy of US from our site brought promising results. Furthermore, there are no trials prospectively investigating these three imaging methods in the same study population. The CANNES study is a prospective multicenter trial comparing diagnostic accuracy of US, PET/CT and DW/MRI in preoperative assessment of pelvic lymph nodes in cervical cancer. The study is designed to establish new standard in preoperative assessment of pelvic lymph nodes in patients with cervical cancer. Ninety-one patients will be enrolled into the study within 36 months and each of them will undergo all three imaging methods. To avoid a bias all imaging examinations will be conducted independently and blinded among sonographers, radiologists and nuclear medicine physicians. By contrast, each surgeon will have all reports from imaging available before procedure to be used as a navigation. Surgical procedures will include sentinel lymph node biopsy, debulking/sampling or systematic dissection of pelvic nodes following current European guidelines.

Detailed Description

CANNES is a single arm, multicenter, prospective imaging trial. Patients referred with histopathologically confirmed cervical cancer will be clinically examined. As standard of care one of imaging method will be performed in preoperative local work-up - ultrasound or DW/MRI. The preference of imaging method of the first choice depends on the institutional practice. Eligible women meeting all inclusion criteria will be provided with the following documents ("Informed consent" and "Information for patients") and the objectives and the course of the study will be discussed with them. After the written consent, patients will be registered into the database using REDCap (Research Electronic Data Capture, www.project-redcap.org) electronic data capture tool. It is a secure, web-based application with controlled access designed to support data capture for research studies, hosted at MD Anderson.

To avoid any bias all imaging examinations will be conducted independently and blinded among sonographers, radologists and nuclear medicine physicians, i.e. without access to the reports from other examinations. In situation that sonographer is gynecologic oncologist, she/he will never perform and report ultrasound and surgery of the same patient. The same radiologist will never report the PET/CT and DW/MRI of the same patient. Examinators performing ultrasound scan and radiologists performing PET/CT or DW/MRI will be well instructed about standardized approach and evaluation of the imaging will follow predefined protocols. If a patient already had PET/CT or DW/MRI done by the referring hospital, the study radiologists decide about the quality of imaging and necessity to repeat them. All scans must be assessed by the radiologists involved in the study. Similarly, ultrasound examination will be only performed by expert sonographers participating in the trial. For every examination, a separate evaluation form (US form, PET/CT form and DW/MRI form) containing only the information of this examination will be used.

Surgery (laparoscopy, laparotomy or robotic surgery) should always be performed within 6 weeks after the first imaging method. Surgical procedure must include SLNB or sampling/debulking of suspicious/enlarged pelvic lymph nodes (± inframesenteric PALND) or systematic PLND. Surgeons will have all reports from ultrasound, PET/CT and DW/MRI available before surgery to be used as a navigation. All radiologically positive lymph nodes must be removed. Surgery evaluation form with precise description of the intraoperative finding will be filled in. Five evaluation forms will be completed (clinical data, US, PET/CT, DW/MRI, surgery) immediately when procedure finished using electronic database. The sixth evaluation form (pathology) will be completed when available by principal investigator.

Conditions

Lymph Node Metastasis; Cervical Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

ultrasound - transvaginal/transrectal + transabdominal

Each patient undergoes at least ultrasound examination and PET-CT.

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

PET-CT (positron emission tomography - computed tomography); DW-MRI (diffusion weighted magnetic resonance imaging)

Eligibility Criteria

Inclusion Criteria

• Histopathologically verified cervical cancer
• FIGO stage IA1 L1 (lymphovascular space involvement) - IIIC2
• Patient eligible for surgery (PLND, sampling or debulking of LNs, SLNB)
• PET/CT scan not contraindicated
• 18 > Age < 80
• Eastern Cooperative Oncology Group (ECOG) performance status grade < 3
• Non-pregnant patient
• Informed consent signed

Exclusion Criteria

• Tumor type other than primary cervical carcinomas
• Second malignant tumor under treatment
• FIGO stage IV (local spread to rectum or bladder, distant metastases)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Charles University, Czech Republic

OTHER

Sponsor Role: collaborator

General University Hospital, Prague

OTHER

Sponsor Role: lead

Responsible Party

Filip Fruhauf

Principial Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Filip Fruhauf

Role: PRINCIPAL_INVESTIGATOR

General University Hospital

Locations

General University Hospital

Prague, , Czechia

Countries

Czechia

Other Identifiers

NU21-03-00461

Identifier Type: -

Identifier Source: org_study_id